Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaAdriano Lazzarin, Miklos Salgo, Bonaventura Clotet et al.|New England Journal of Medicine|2003Cited by 653
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean‐Michel Molina, Steven L. Chuck, Anthony LaMarca et al.|The Lancet Infectious Diseases|2011Cited by 172
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtideBonaventura Clotet, Jonathan Schapiro, François Raffi et al.|AIDS|2004Cited by 72
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1Beatriz Mothe, Constanza Lucero, Núria Climent et al.|Journal of Antimicrobial Chemotherapy|2015Cited by 65